News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Traws Pharma (NASDAQ:TRAW) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.

Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients [Yahoo! Finance]

Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients

Traws Pharma (NASDAQ:TRAW) was upgraded by analysts at Zacks Research to a "hold" rating.

Traws Pharma (NASDAQ:TRAW) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $8.00 price target on the stock.

Form 8-K Traws Pharma, Inc. For: Dec 17

Form 4 Traws Pharma, Inc. For: Dec 12 Filed by: Leaman John Harold

Form 4 Traws Pharma, Inc. For: Dec 12 Filed by: Clarke Trafford

Form 4 Traws Pharma, Inc. For: Dec 12 Filed by: CAUTREELS WERNER

Form 4 Traws Pharma, Inc. For: Dec 12 Filed by: Shoemaker Mary Teresa

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}